Safety of Escitalopram in Congestive Heart Disease

Evidence Supporting Safety

SSRIs, including escitalopram, have been shown to be safe in patients with heart failure and coronary heart disease, though their efficacy in treating depression is mixed, according to the American Heart Association 1
The EsDEPACS study demonstrated lower major adverse cardiac events after median 8.1 years follow-up in patients with recent acute coronary syndrome treated with escitalopram compared to placebo, as recommended by the American College of Cardiology (40.9% vs 53.6%; hazard ratio 0.69) 3

Escitalopram carries a higher risk of QTc prolongation compared to sertraline, making sertraline the preferred first-line SSRI for patients with extensive cardiac history, as suggested by the European Society of Cardiology 1, 2
Monitor QTc interval if the patient is on other QT-prolonging medications or has baseline cardiac conduction abnormalities, according to the European Heart Journal 4, 2

Start escitalopram at 10 mg once daily in the morning, as recommended by the American College of Cardiology 5
Prefer sertraline over escitalopram in patients with extensive cardiac history, baseline QTc prolongation, or concurrent use of other QT-prolonging medications, as suggested by the American Heart Association 2

Mirtazapine has been shown to be safe in patients with cardiovascular disease and can be combined with escitalopram for treatment-resistant depression, according to the American Psychiatric Association 5, 1
However, avoid mirtazapine in elderly patients with orthostatic hypotension or fall risk, as recommended by the European Society of Cardiology 2
Monoamine oxidase inhibitors and tricyclic antidepressants should be avoided due to significant cardiovascular side effects, including hypertension, hypotension, and arrhythmias, as suggested by the American College of Cardiology 1, 2